Palifermin
- Atc Codes:V03AF08
- CAS Codes:162394-19-6
- PHARMGKB ID:162394-19-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Kepivance; Belgium: Kepivance; Bulgaria: Kepivance; Cyprus: Kepivance; Czech Republic: Kepivance; Denmark: Kepivance; Estonia: Kepivance; Finland: Kepivance; France: Kepivance; Germany: Kepivance; Greece: Kepivance; Hungary: Kepivance; Ireland: Kepivance; Italy: Kepivance; Latvia: Kepivance; Lithuania: Kepivance; Luxembourg: Kepivance; Malta: Kepivance; Netherlands: Kepivance; Poland: Kepivance; Portugal: Kepivance; Romania: Kepivance; Slovakia: Kepivance; Slovenia: Kepivance; Spain: Kepivance; Sweden: Kepivance; UK: Kepivance.
North America
Canada: Kepivance; USA: Kepivance.
Drug combinations
Chemistry
Palifermin: C~729~H~1156~N~204~O~207~S~10~. Mw: approx. 16300.01. 24-163 fibroblast growth factor 7 (human). CAS-162394-19-6 (2002).
Pharmacologic Category
Skin and Mucous Membrane Agents; Cell Stimulants and Proliferants; Keratinocyte Growth Factor. (ATC-Code: V03AF08).
Mechanism of action
Recombinant keratinocyte growth factor produced in E. coli. Binds to keratinocyte growth factor receptor resulting in proliferation, differentiation and migration of epithelial cells in multiple tissues.
Therapeutic use
Decreases incidence and severity of severe oral mucositis associated with hematologic malignancies.
Pregnancy and lactiation implications
Embryotoxic in animal studies at doses also associated with maternal toxicity. There are no adequate, well-controlled studies in pregnant women. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to palifermin, E. coli-derived proteins, or any component of the formulation.
Warnings and precautions
Mucocutaneous effects (edema, erythema, pruritus, rash, oral/perioral dysesthesia, taste alteration, tongue discoloration, and tongue thickening) may occur. May increase severity and duration of mucositis if administered within 24 hours of chemotherapy. Enhances epithelial tumor cell lines in vitro.